IPA is ticker

Immunoprecise (IPA) is not a buy at this time. Here's why: 1. **Technical Indicators Suggest Caution**: The stock's technical indicators suggest a strong sell signal. The RSI is at 78.32, which is considered overbought and could indicate a potential pullback. Additionally, the MACD is at 0.1, which is close to the neutral line and not indicating a strong buying momentum. 2. **Market Sentiment and Recent Performance**: The stock has recently surged by 21.15% on the news of its AI-driven drug development platform, LENSai™, but this surge is not supported by the underlying financials. The company's net income for the quarter ending Q4 2025 is -$1.74 million, and it has a negative P/E ratio of -5.51, which suggests that the company is not profitable as of the latest report period. 3. **Resistance and Support Levels**: The stock is currently trading below its resistance level of $2.72 but above its support level of $1.85. However, the closing price of $2.615 is closer to the resistance level, which could indicate a potential reversal or a pullback. |code|Ticker|Name|Date|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|20250819|1.8500|2.7200|186| |code|Ticker|Name|Date|Closing Price|market_code| |---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|20240819|0.9601|186| |IPA|IPA.O|Immunoprecise|20240820|0.812|186| |IPA|IPA.O|Immunoprecise|20240821|0.8899|186| |IPA|IPA.O|Immunoprecise|20240822|0.835|186| |IPA|IPA.O|Immunoprecise|20240823|0.81|186| |IPA|IPA.O|Immunoprecise|20240826|0.7933|186| |IPA|IPA.O|Immunoprecise|20240827|0.7663|186| |IPA|IPA.O|Immunoprecise|20240828|0.781|186| |IPA|IPA.O|Immunoprecise|20240829|0.7646|186| |IPA|IPA.O|Immunoprecise|20240830|0.755|186| 4. **Moving Averages**: The stock's moving averages are also indicative of a potential decline. The 5-day moving average is $2.27, the 10-day moving average is $2.1, and the 50-day moving average is $1.55. The fact that the stock price is below these moving averages could suggest a bearish trend. |code|Ticker|Name|Date|Moving Average|market_code| |---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|20250819|2.2650|186| 5. **Fundamental Analysis**: The company's financials show a significant loss in net income, with a net income growth rate of 87.07% YoY, which is not reflective of a profitable company. The revenue growth rate is positive at 13.92%, but this is not enough to justify the high valuation of the company. |code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code| |---|---|---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|2024 Q1|63.028158971324764|23.163410368774624|62.59352451574608|186| |IPA|IPA.O|Immunoprecise|2024 Q2|68.99470509408852|12.242055700022105|68.46271995940842|186| |IPA|IPA.O|Immunoprecise|2024 Q3|45.22330983531252|15.588381274465776|49.43210013872685|186| |IPA|IPA.O|Immunoprecise|2024 Q4|-247.3718591766569|16.25715086098274||186| |IPA|IPA.O|Immunoprecise|2025 Q1|-20.986576126776345|-4.373683605050126|-10.73039975593934|186| |IPA|IPA.O|Immunoprecise|2025 Q2|-19.260716457343836|12.076452629787719|-1.2805167846326644|186| |IPA|IPA.O|Immunoprecise|2025 Q3|-766.7574378950792|6.682545331567112|-612.1176972444613|186| |IPA|IPA.O|Immunoprecise|2025 Q4|87.06609501617484|13.91649359889979||186| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|2025 Q1|-20.986576126776345|-3165518.86239|186| |IPA|IPA.O|Immunoprecise|2025 Q2|-19.260716457343836|-2036859.7347|186| |IPA|IPA.O|Immunoprecise|2025 Q3|-766.7574378950792|-1.711411534623E7|186| |IPA|IPA.O|Immunoprecise|2025 Q4|87.06609501617484|-1736021.8459|186| |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|2025 Q1|-4.373683605050126|4166072.96143|186| |IPA|IPA.O|Immunoprecise|2025 Q2|12.076452629787719|4886708.1375|186| |IPA|IPA.O|Immunoprecise|2025 Q3|6.682545331567112|4891451.30313|186| |IPA|IPA.O|Immunoprecise|2025 Q4|13.91649359889979|5608129.8039|186| |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |IPA|IPA.O|Immunoprecise|2025 Q1|-10.73039975593934|-0.1187366415|186| |IPA|IPA.O|Immunoprecise|2025 Q2|-1.2805167846326644|-0.071804691|186| |IPA|IPA.O|Immunoprecise|2025 Q3|-612.1176972444613|-0.5248508958|186| 6. **Market Position and Competition**: The company operates in the Pharmaceuticals sector and faces competition from other companies in the AI-driven drug development space. The market's perception of the company's technology and ability to commercialize its platform is key to its future success, which is currently not clear. In conclusion, while there is potential for growth in the AI-driven drug development space, the current financial and technical indicators do not support a buy recommendation for Immunoprecise at this time. Investors should exercise caution and consider the high risk associated with the stock's recent surge in price.